BRIDGEBIO PHARMA INC

NASDAQ: BBIO (BridgeBio Pharma, Inc.)

最近更新时间: 6天之前, 11:27AM

27.49

-0.18 (-0.65%)

前收盘价格 27.67
收盘价格 27.90
成交量 1,404,756
平均成交量 (3个月) 2,050,909
市值 5,195,335,168
价格/销量 (P/S) 22.77
52周波幅
21.62 (-21%) — 44.32 (61%)
利润日期 20 Feb 2025 - 24 Feb 2025
营业毛利率 -201.53%
营业利益率 (TTM) -6,849.52%
稀释每股收益 (EPS TTM) -2.42
季度收入增长率 (YOY) -33.20%
流动比率 (MRQ) 3.19
营业现金流 (OCF TTM) -450.22 M
杠杆自由现金流 (LFCF TTM) -365.12 M
资产报酬率 (ROA TTM) -48.88%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 BridgeBio Pharma, Inc. 看涨 看涨

AIStockmoo 评分

1.3
分析师共识 5.0
内部交易活动 3.0
价格波动 -2.0
技术平均移动指标 0.0
技术振荡指标 0.5
平均 1.30

相关股票

股票 市值 DY P/E(TTM) P/B
BBIO 5 B - - -
VKTX 5 B - - 5.75
CRNX 5 B - - 6.70
KRYS 5 B - 87.77 5.77
ACAD 3 B - 21.63 4.67
DYN 3 B - - 4.23

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth
内部持股比例 5.40%
机构持股比例 94.45%
52周波幅
21.62 (-21%) — 44.32 (61%)
目标价格波幅
45.00 (63%) — 49.00 (78%)
49.00 (HC Wainwright & Co., 78.25%) 购买
47.00 (70.97%)
45.00 (B of A Securities, 63.70%) 购买
平均值 47.00 (70.97%)
总计 4 购买
平均价格@调整类型 27.07
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 16 Dec 2024 49.00 (78.25%) 购买 27.71
25 Nov 2024 49.00 (78.25%) 购买 27.19
B of A Securities 25 Nov 2024 45.00 (63.70%) 购买 27.19
Scotiabank 25 Nov 2024 48.00 (74.61%) 购买 27.19
15 Nov 2024 45.00 (63.70%) 购买 23.72
Leerink Partners 17 Oct 2024 46.00 (67.33%) 购买 26.19
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
TRIMARCHI THOMAS 29.04 - 50,000 1,452,000
累积净数量 50,000
累积净值 ($) 1,452,000
累积平均购买 ($) 29.04
累积平均卖出 ($) -
名称 持有人 日期 类型 数量 价格 价值 ($)
TRIMARCHI THOMAS 职员 10 Dec 2024 获得 (+) 50,000 29.04 1,452,000
日期 类型 细节
13 Dec 2024 公告 Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
22 Nov 2024 公告 Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
18 Nov 2024 公告 BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
18 Nov 2024 公告 Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
12 Nov 2024 公告 BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
05 Nov 2024 公告 BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
24 Oct 2024 公告 BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
03 Oct 2024 公告 BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
30 Sep 2024 公告 BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
27 Sep 2024 公告 BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2024 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票